Diseases of the Collagen Molecule C
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Boards' Fodder
boards’ fodder Cosmeceuticals Contributed by Elisabeth Hurliman, MD, PhD; Jennifer Hayes, MD; Hilary Reich MD; and Sarah Schram, MD. INGREDIENT FUNCTION MECHANISM ASSOCIATIONS/SIDE EFFECTS Vitamin A/ Antioxidant (reduces free Affects gene transcription Comedolysis epidermal thickening, dermal Derivatives (retinal, radicals, lowers concentration differentiation and growth of regeneration, pigment lightening retinol, retinoic of matrix metalloproteinases cells in the skin acid, provitamin reduces collagen degradation) Side effects: Irritation, erythema, desquamation A, asthaxanthin, Normalizes follicular Elisabeth Hurliman, lutein) epithelial differentiation and keratinization MD, PhD, is a PGY-4 dermatology resident Vitamin C (L Secondary endogenous Ascorbic acid: necessary L-ascorbic acid + alpha-tocopherol (vitamin E)= ascorbic acid, antioxidant in skin cofactor for prolylhydroxylase UVA and UVB protection at University of tetrahexyldecyl and lysyl hydroxylase Minnesota department ascorbate) Lightens pigment Zinc, resveratrol, L-ergothioneine and tyrosine add of dermatology. (affects melanogenesis) L-ascorbic acid: scavenges to vitamin C bioavailability free oxygen radicals, Protects Vitamin E from oxidation stimulates collagen synthesis Improves skin texture and hydration May interrupt melanogenesis by interacting with copper ions Vitamin E/ Primary endogenous antioxidant Prevents lipid peroxidation; Alpha tocopherol is the most physiologically Tocopherols, in skin scavenges free oxygen active isomer Jennifer Hayes, MD, Tocotrienols -
Report on the 8Th International Workshop on the CCN Family of Genes – Nice November 3–8, 2015
J. Cell Commun. Signal. (2016) 10:77–86 DOI 10.1007/s12079-016-0317-y EDITORIAL Report on the 8th international workshop on the CCN family of genes – Nice November 3–8, 2015 Bernard Perbal1 & Lester Lau 2 & Karen Lyons3 & Satoshi Kubota4 & Herman Yeger5 & Gary Fisher6 Received: 29 January 2016 /Accepted: 29 January 2016 /Published online: 26 February 2016 # The International CCN Society 2016 The 8th international workshop on the CCN family of genes was able and enthusiastic about participating with us in the full was held for a second time in Nice, from November 3rd to 8th, sessions of the meeting. It is always a unique and fruitful 2015. Under particularly sunny and warm weather everyone opportunity for all participants, either young or established enjoyed the charms of the Mediterranean coastline. scientists, to share time with the awardees. Thanks to Annick Perbal, the social events during the meet- This year we also had the pleasure to welcome Robert ing were a real success and were truly well appreciated by all. Baxter, a former ICCNS-Springer awardee, who flew in from The choice of the Westminster hotel was an excellent one. Australia to join us and present a special conference on the role of This year the ICCNS honored and warmly welcomed IGFBP3 in the breast cancer response to DNA damaging Judith Campisi, the recipient of the 2015 ICCNS-Springer therapy. award, who accepted to present a conference on senescence Those who did not have the opportunity to make it at the time and cancer. We are grateful to Judith Campisi who came a Robert Baxter received the award in Sydney, could then enjoy long way from San Francisco, despite being under the weather sharing experiences and discuss possible levels of interactions with a bad cold and sore throat. -
Undenatured Type II Collagen Mechanism of Action
Undenatured Type II Collagen Mechanism of Action Page Executive Summary .................... 2 Animal Research ......................... 3 In Vitro Research ........................ 4 For Professional Use Only UC-II® Undenatured Type II Collagen (Mechanism of Action) Executive Summary UC-II® undenatured type II collagen is a patented form of collagen with undenatured (native) type II collagen for joint health support. A small amount (40 mg/day) is believed to work by inducing a process known as oral tolerance that ultimately engages the immune system in the repair of its own joint cartilage. Oral tolerance is an immune process that allows the body to distinguish between innocuous compounds such as dietary proteins and intestinal bacteria and potentially harmful foreign invaders. In the digestive tract, oral tolerance occurs in the gut-associated lymphoid tissue (GALT), considered to be the body’s most abundant lymphoid tissue. The GALT is primarily composed of mesenteric lymph nodes and patches of lymphoid tissue surrounding the small intestine called Peyer’s patches. It is in the Peyer’s patches, which contain an organized collection of immune cells, where most of the immune responses in the digestive tract are generated. Through a cascade of immunological events, Peyer’s patches take in and screen compounds from the gut lumen and, depending on the compound, turn the body’s immune response on or off (Weiner et al1). Researchers believe UC-II® undenatured type II collagen induces a form of oral tolerance that results from exposure to a compound in small amounts. More specifically, UC-II® undenatured type II collagen is believed to be transported across the gut epithelial cells to the underlying immune cells in the Peyer’s patches where it activates naive T cells to become T regulatory (Treg) cells that specifically target type II collagen. -
Regulation of Procollagen Amino-Propeptide Processing During Mouse Embryogenesis by Specialization of Homologous ADAMTS Protease
DEVELOPMENT AND DISEASE RESEARCH ARTICLE 1587 Development 133, 1587-1596 (2006) doi:10.1242/dev.02308 Regulation of procollagen amino-propeptide processing during mouse embryogenesis by specialization of homologous ADAMTS proteases: insights on collagen biosynthesis and dermatosparaxis Carine Le Goff1, Robert P. T. Somerville1, Frederic Kesteloot2, Kimerly Powell1, David E. Birk3, Alain C. Colige2 and Suneel S. Apte1,* Mutations in ADAMTS2, a procollagen amino-propeptidase, cause severe skin fragility, designated as dermatosparaxis in animals, and a subtype of the Ehlers-Danlos syndrome (dermatosparactic type or VIIC) in humans. Not all collagen-rich tissues are affected to the same degree, which suggests compensation by the ADAMTS2 homologs ADAMTS3 and ADAMTS14. In situ hybridization of Adamts2, Adamts3 and Adamts14, and of the genes encoding the major fibrillar collagens, Col1a1, Col2a1 and Col3a1, during mouse embryogenesis, demonstrated distinct tissue-specific, overlapping expression patterns of the protease and substrate genes. Adamts3, but not Adamts2 or Adamts14, was co-expressed with Col2a1 in cartilage throughout development, and with Col1a1 in bone and musculotendinous tissues. ADAMTS3 induced procollagen I processing in dermatosparactic fibroblasts, suggesting a role in procollagen I processing during musculoskeletal development. Adamts2, but not Adamts3 or Adamts14, was co-expressed with Col3a1 in many tissues including the lungs and aorta, and Adamts2–/– mice showed widespread defects in procollagen III processing. Adamts2–/– mice had abnormal lungs, characterized by a decreased parenchymal density. However, the aorta and collagen fibrils in the aortic wall appeared normal. Although Adamts14 lacked developmental tissue-specific expression, it was co-expressed with Adamts2 in mature dermis, which possibly explains the presence of some processed skin procollagen in dermatosparaxis. -
Enzymatic Encoding Methods for Efficient Synthesis Of
(19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN, -
Rational Design of Resveratrol O-Methyltransferase for the Production of Pinostilbene
International Journal of Molecular Sciences Article Rational Design of Resveratrol O-methyltransferase for the Production of Pinostilbene Daniela P. Herrera 1 , Andrea M. Chánique 1,2 , Ascensión Martínez-Márquez 3, Roque Bru-Martínez 3 , Robert Kourist 2 , Loreto P. Parra 4,* and Andreas Schüller 4,5,* 1 Department of Chemical and Bioprocesses Engineering, School of Engineering, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Santiago 7820244, Chile; [email protected] (D.P.H.); [email protected] (A.M.C.) 2 Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria; [email protected] 3 Department of Agrochemistry and Biochemistry, Faculty of Science and Multidisciplinary Institute for Environmental Studies “Ramon Margalef”, University of Alicante, 03690 Alicante, Spain; [email protected] (A.M.-M.); [email protected] (R.B.-M.) 4 Institute for Biological and Medical Engineering, Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Santiago 7820244, Chile 5 Department of Molecular Genetics and Microbiology, School of Biological Sciences, Pontificia Universidad Católica de Chile, Av. Libertador Bernardo O’Higgins 340, Santiago 8320000, Chile * Correspondence: [email protected] (L.P.P.); [email protected] (A.S.) Abstract: Pinostilbene is a monomethyl ether analog of the well-known nutraceutical resveratrol. Both compounds have health-promoting properties, but the latter undergoes rapid metabolization and has low bioavailability. O-methylation improves the stability and bioavailability of resveratrol. In plants, these reactions are performed by O-methyltransferases (OMTs). Few efficient OMTs that Citation: Herrera, D.P.; Chánique, monomethylate resveratrol to yield pinostilbene have been described so far. -
Table 2. Significant
Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S. -
Mutant IDH, (R)-2-Hydroxyglutarate, and Cancer
Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer Julie-Aurore Losman1 and William G. Kaelin Jr.1,2,3 1Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA; 2Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA Mutations in metabolic enzymes, including isocitrate whether altered cellular metabolism is a cause of cancer dehydrogenase 1 (IDH1) and IDH2, in cancer strongly or merely an adaptive response of cancer cells in the face implicate altered metabolism in tumorigenesis. IDH1 of accelerated cell proliferation is still a topic of some and IDH2 catalyze the interconversion of isocitrate and debate. 2-oxoglutarate (2OG). 2OG is a TCA cycle intermediate The recent identification of cancer-associated muta- and an essential cofactor for many enzymes, including tions in three metabolic enzymes suggests that altered JmjC domain-containing histone demethylases, TET cellular metabolism can indeed be a cause of some 5-methylcytosine hydroxylases, and EglN prolyl-4-hydrox- cancers (Pollard et al. 2003; King et al. 2006; Raimundo ylases. Cancer-associated IDH mutations alter the enzymes et al. 2011). Two of these enzymes, fumarate hydratase such that they reduce 2OG to the structurally similar (FH) and succinate dehydrogenase (SDH), are bone fide metabolite (R)-2-hydroxyglutarate [(R)-2HG]. Here we tumor suppressors, and loss-of-function mutations in FH review what is known about the molecular mechanisms and SDH have been identified in various cancers, in- of transformation by mutant IDH and discuss their im- cluding renal cell carcinomas and paragangliomas. -
Native Type II Collagen for Joint Health: Small Dose, Big Benefits
Print this Document! Native Type II Collagen for Joint Health: Small Dose, Big Benefits By Cai Berg Collagens are the most abundant family of proteins in the extracellular matrix of connective tissues. They perform a variety of biological functions, the best known of which is providing the structural framework for tissues throughout the body. Based on their supramolecular organization, 26 different types of collagen have been identified, each with its own role and position in the body. Type II collagen is the main structural protein in the cartilage. It provides tensile strength and toughness to the tissue. Joint disorders involving inflammation and cartilage erosion, such as arthritis, are often characterized by an autoimmune component in which the immune system acts against the body's own type II collagen. Studies have shown that supplementing native (undenatured) type II collagen can help modulate the destructive immune response against endogenous type II collagen to support joint health and comfort.1 Not All Collagens Are Equal Collagen and collagen derivatives have been investigated and employed for joint nourishment for decades. Collagen products are defined by their degree of hydrolyzation and their molecular weight as either undenatured (native) collagen, collagen hydrolysate (hydrolyzed collagen) or gelatin. Undenatured (native) collagen has the highest molecular weight (300 kDA), while hydrozyled collagen ranges from 2 to 9 kDa. Unlike gelatin and hydrolyzed collagen supplements, which are intended to be absorbed to augment the collagen needs of various cells and tissues, native type II collagen supplements work through a mechanism known as oral tolerization. This immune-mediated process involves ingestion of an autoantigen (in this case, type II collagen) in order to suppress the immune response against endogenous tissue. -
Cloning of ADAMTS2 Gene and Colony Formation Effect of ADAMTS2 in Saos-2 Cell Line Under Normal and Hypoxic Conditions, ADYU J SCI, 10(2), 413-426
Aydogan Türkoğlu & Gültekin Tosun (2020) Cloning of ADAMTS2 Gene and Colony Formation Effect of ADAMTS2 in Saos-2 Cell Line Under Normal and Hypoxic Conditions, ADYU J SCI, 10(2), 413-426 Cloning of ADAMTS2 Gene and Colony Formation Effect of ADAMTS2 in Saos-2 Cell Line Under Normal and Hypoxic Conditions Sümeyye AYDOGAN TÜRKOĞLU1,*, Sinem GÜLTEKİN TOSUN2 1Balıkesir University, Faculty of Science and Literature, Department of Molecular Biology and Genetics, Balıkesir, Turkey [email protected], ORCID: 0000-0003-1754-0700 2Erciyes University, Institute of Health Sciences, Faculty of Veterinary Medicine, Department of Genetics, Kayseri, Turkey [email protected], ORCID: 0000-0002-3927-0089 Received: 03.05.2020 Accepted: 25.09.2020 Published: 30.12.2020 Abstract ADAMTS2 (a disintegrin and metalloproteinase with thrombospondin motifs 2), an N- propeptidase isoenzyme, is an enzyme involved in collagen biosynthesis by providing the amino ends of procollagen to be cut away. ADAMTS2 has anti-angiogenic activity as well as provides the processing of collagen. With this activity, it has become a target in cancer studies. Hypoxic regulation is a process that affects the expression of a large number of genes at the cellular level. Within the scope of our study, the cloning of the ADAMTS2 gene and its expression in Saos-2 (human bone carcinoma) cell line were performed ectopically. For this purpose, the transient transfection of the expression vector containing ADAMTS2 coding sequence was transfected by the calcium-phosphate precipitation method. Recombinant ADAMTS2 mRNA expression was checked by Real-Time PCR in Saos-2 cells. It was observed that there was a 50-fold increase in ADAMTS2 mRNA expression in the transfected Saos-2 cells compared to the control group. -
Page Numbers in Bold Indicate Main Discus- Sion of Topic. Page Numbers
168397_P489-520.qxd7.0:34 Index 6-2-04 26p 2010.4.5 10:03 AM Page 489 source of, 109, 109f pairing with thymine, 396f, 397, 398f in tricarboxylic acid cycle, 109–111, 109f Adenine arabinoside (vidarabine, araA), 409 Acetyl CoA-ACP acetyltransferase, 184 Adenine phosphoribosyltransferase (APRT), Index Acetyl CoA carboxylase, 183, 185f, 190 296, 296f in absorptive/fed state, 324 Adenosine deaminase (ADA), 299 allosteric activation of, 183–184, 184f deficiency of, 298, 300f, 301–302 allosteric inactivation of, 183, 184f gene therapy for, 485, 486f dephosphorylation of, 184 Adenosine diphosphate (ADP) in fasting, 330 in ATP synthesis, 73, 77–78, 78f Page numbers in bold indicate main discus- hormonal regulation of, 184, 184f isocitrate dehydrogenase activation by, sion of topic. Page numbers followed by f long-term regulation of, 184 112 denote figures. “See” cross-references direct phosphorylation of, 183–184 transport of, to inner mitochondrial short-term regulation of, 183–184, 184f membrane, 79 the reader to the synonymous term. “See Acetyl CoA carboxylase-2 (ACC2), 191 in tricarboxylic acid cycle regulation, 114, also” cross-references direct the reader to N4-Acetylcytosine, 292f 114f related topics. [Note: Positional and configura- N-Acetyl-D-glucosamine, 142 in urea cycle, 255–256 N-Acetylgalactosamine (GalNAc), 160, 168 ribosylation, 95 tional designations in chemical names (for N-Acetylglucosamindase deficiency, 164f Adenosine monophosphate (AMP; also called example, “3-“, “α”, “N-“, “D-“) are ignored in N-Acetylglucosamine (GlcNAc), -
Review Article
REVIEW ARTICLE COLLAGEN METABOLISM COLLAGEN METABOLISM Types of Collagen 228 Structure of Collagen Molecules 230 Synthesis and Processing of Procollagen Polypeptides 232 Transcription and Translation 233 Posttranslational Modifications 233 Extracellular Processing of Procollagen and Collagen Fibrillogenesis 240 Functions of Collagen in Connective rissue 243 Collagen Degradation 245 Regulation of the Metabolism of Collagen 246 Heritable Diseases of Collagen 247 Recessive Dermatosparaxis 248 Recessive Forms of EDS 251 EDS VI 251 EDS VII 252 EDS V 252 Lysyl Oxidase Deficiency in the Mouse 253 X-Linked Cutis Laxa 253 Menke's Kinky Hair Syndrome 253 Homocystinuria 254 EDS IV 254 Dominant Forms of EDS 254 Dominant Collagen Packing Defect I 255 Dominant and Recessive Forms of Osteogenesis Imperfecta 258 Dominant and Recessive Forms of Cutis Laxa 258 The Marfan Syndrome 259 Acquired Diseases and Repair Processes Affecting Collagen 259 Acquired Changes in the Types of Collagen Synthesis 260 Acquired Changes in Amounts of Collagen Synthesized 263 Acquired Changes in Hydroxylation of Proline and Lysine 264 Acquired Changes in Collagen Cross-Links 265 Acquired Defects in Collagen Degradation 267 Conclusion 267 Bibliography 267 Collagen Metabolism A Comparison of Diseases of Collagen and Diseases Affecting Collagen Ronald R. Minor, VMD, PhD COLLAGEN CONSTITUTES approximately one third of the body's total protein, and changes in synthesis and/or degradation of colla- gen occur in nearly every disease process. There are also a number of newly described specific diseases of collagen in both man and domestic animals. Thus, an understanding of the synthesis, deposition, and turnover of collagen is important for the pathologist, the clinician, and the basic scientist alike.